What financial assistance is available specifically for HER2-Low Breast Cancer patients

Financial Assistance for HER2-Low Breast Cancer Patients

I appreciate your question about financial support. Let me be direct: the sources I have access to don't contain specific financial assistance programs exclusively for HER2-low breast cancer patients. However, I can share what IS available for breast cancer patients more broadly, and explain why HER2-low is particularly relevant to treatment access.

Why HER2-Low Status Matters Financially

According to the CancerPatientLab webinars on proteomic testing, HER2-low breast cancer recently opened up new treatment options. Specifically, trastuzumab deruxtecan (Enhertu) — an antibody-drug conjugate — was FDA-approved for HER2-low patients after showing a 24-month overall survival compared to 17 months with chemotherapy alone.

This is important financially because:

• Newer targeted drugs often have patient assistance programs from manufacturers
• Insurance coverage decisions are evolving as these treatments become standard of care
• Your specific HER2 status may qualify you for programs that didn't exist before

General Financial Resources for Breast Cancer Patients

Based on the available resources, here are assistance options:

Manufacturer Patient Assistance Programs

According to the CancerPatientLab webinars on accessing cancer treatments:

• Pharmaceutical companies provide protocols for patients needing financial help with their drugs
• For Enhertu (your potential HER2-low treatment), AstraZeneca has patient assistance available
• A billing professional can contact the manufacturer's program directly on your behalf

Broader Financial Navigation Resources

The webinars reference several organizations that help with cancer treatment costs:

1. Nancy's List (nancyslist.org)

   • Comprehensive financial resources for cancer patients
   • Medication assistance programs
   • Quality of life support

2. The Assistance Fund

   • Helps negotiate lower drug prices
   • Guides patients through financial toxicity issues

3. GoodRx & QuickRx

   • Compare drug prices across pharmacies
   • Can significantly reduce out-of-pocket costs

4. The Patient Advocacy Foundation

   • Case managers advocate on your behalf
   • Help with insurance navigation

Questions to Ask Your Oncology Team

Since HER2-low treatment is relatively new, your healthcare team is your best resource:

1. "Are there patient assistance programs available for Enhertu or other HER2-targeted therapies I might receive?"

2. "Can your billing department help me apply for manufacturer assistance programs?"

3. "Will my insurance cover Enhertu, or do we need to request prior authorization?"

4. "Are there clinical trials for HER2-low breast cancer that might reduce my out-of-pocket costs?"

5. "Can you refer me to a financial counselor who specializes in cancer care?"

Important Context

According to the CancerPatientLab webinars, insurance coverage for newer precision medicine treatments is evolving. One case study described a patient with low HER2 amplification breast cancer whose insurance initially resisted coverage, but after discussion with the care team and presentation of recent evidence (like data from ASCO meetings), the insurance company approved the treatment.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.